Future study will focus on designing a liposome-based system for delivery of SAAL1 siRNA in combination with sorafenib or foretinib to observe antitumor efficacy in an orthotopic HCC mouse model [33]. Here, SAAL1 is linked to hepatocellular carcinoma.